Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861263 | 0.89 | SLC6A3 (0.46) | ROCK2ROCK1 | |
| SCHEMBL21359504 | 0.79 | ACMSD (0.54) | ROCK2ACMSDROCK1MIFCLK2 | |
| SCHEMBL21359523 | 0.75 | MIF (0.66) | ROCK2ACMSDROCK1MIFCLK2 | |
| SCHEMBL781536 | 0.72 | ROCK2 (0.40) | ROCK2CLK2HIPK1DYRK2HIPK2 | |
| SCHEMBL2458568 | 0.72 | AKT2 (0.59) | ROCK2CLK2HIPK1DYRK2HIPK2 | |
| SCHEMBL22861261 | 0.72 | AKT1 (0.56) | ROCK2ACMSDROCK1CLK2HIPK1 | |
| Hydrochloric Acid SCHEMBL16162193 | 0.72 | FGFR1 (0.40) | ROCK2CLK2HIPK1DYRK2HIPK2 | |
| SCHEMBL22861323 | 0.71 | SLC6A3 (0.64) | ROCK2ROCK1CLK2HIPK1DYRK2 | |
| SCHEMBL21359417 | 0.70 | MCL1 (0.47) | ROCK2ROCK1ACLYAKT1AKT2 | |
| SCHEMBL21359390 | 0.70 | MIF (0.51) | ROCK2ROCK1MIFACLYAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019178480-A1 | PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | YALE UNIVERSITY (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | ROCK2 1167/4885ACMSD 4775/4885ROCK1 1458/4885 |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | ROCK2 1259/4885ACMSD 4774/4885ROCK1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.